New treatments of pulmonary arterial hypertension;Nouveaux traitements de l'hypertension artérielle pulmonaire

Medecine et Hygiene

Volumn 62, Issue 2475, 2004, Pages 641-646

  Sitbon, Oliver ^a   Jaïs, Xavier ^a   Humbert, Marc ^a   Ioos, Vincent ^a   Hamid, Abdul Monem ^a   Simonneau, Gérald ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

'AIR'; 'ALPHABET'; BERAPROST; BOSENTAN; BREATHE 1; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ETUDE PILOTE; ILOPROST; PROSTACYCLIN DERIVATIVE; UNIPROST; VASODILATOR AGENT;

ALGORITHM; ARTERY INTIMA PROLIFERATION; BRONCHUS MUSCLE; FIBROMUSCULAR DYSPLASIA; HUMAN; HYPERPLASIA; PATIENT CARE; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; VASCULAR DISEASE; VASOCONSTRICTION;

EID: 1842481640     PISSN: 00256749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004 (in press).
2. Rubin LJ. Therapy of pulmonary hypertension: The evolution from vasodilators to antiproliferative agents. Am J Respir Crit Care Med 2002; 166: 1309-10.
3. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MO, Frye RL. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984; 70: 580-7.
4. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
5. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective study. Ann Intern Med 1991; 115: 343-9.
6. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265-70.
7. Sitbon O, Humbert M, Ioos V, et al. Who benefits from long-term calcium-channel blocker (CCB) therapy in primary pulmonary hypertension (PPH)? Am J Respir Crit Care Med 2003; 167: A440 (Abstract).
8. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-302.
9. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. Prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-8.
10. McLaughlin W, Shillington A, Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002; 106: 1477-82.
11. Simonneau G, Barst RJ, Galie N, et al. Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-4.
12. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-502.
13. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost Therapy for Pulmonary Arterial Hypertension. J Am Coll Cardiol 2003; 41: 2119-25.
14. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of pulmonary hypertension with aerolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342: 1866-70.
15. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-9.
16. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001; 358: 1119-23.
17. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346; 896-903.
18. Sitbon O, Badesch DB, Channick RN, et al. Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients with Pulmonary Arterial Hypertension: A One Year Follow-up Study. Chest 2003; 124: 247-54.
19. McLaughlin V, Sitbon O, Rubin L, et al. The Effect of First-Line Bosentan on Survival of Patients with Primary Pulmonary Hypertension. Am J Respir Crit Care Med 2003; 167: A442 (abstract).
20. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136: 515-22.